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Abstract
Background
Health benefits of postpartum antiretroviral therapy (ART) for human immunodeficiency
virus (HIV) positive women with high CD4+ T-counts have not been assessed in randomized
trials.
Methods
Asymptomatic, HIV-positive, non-breastfeeding women with pre-ART CD4+ T-cell counts
400 cells/mm3 started on ART during pregnancy were randomized up to 42 days after deliv-
ery to continue or discontinue ART. Lopinavir/ritonavir plus tenofovir/emtricitabine was the
preferred ART regimen. The sample size was selected to provide 88% power to detect a
50% reduction from an annualized primary event rate of 2.07%. A post-hoc analysis evalu-
ated HIV/AIDS-related and World Health Organization (WHO) Stage 2 and 3 events. All
analyses were intent to treat.
Results
1652 women from 52 sites in Argentina, Botswana, Brazil, China, Haiti, Peru, Thailand and
the US were enrolled (1/2010-11/2014). Median age was 28 years and major racial catego-
ries were Black African (28%), Asian (25%) White (15%). Median entry CD4 count was 696
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cells/mm3 (IQR 575–869), median ART exposure prior to delivery was 19 weeks (IQR 13–
24) and 94% had entry HIV-1 RNA < 1000 copies/ml. After a median follow-up of 2.3 years,
the primary composite endpoint rate was significantly lower than expected, and not signifi-
cantly different between arms (continue arm 0.21 /100 person years(py); discontinue 0.31/
100 py, Hazard ratio (HR) 0.68, 95% CI: 0.19, 2.40). WHO Stage 2 and 3 events were signif-
icantly reduced with continued ART (2.08/100 py vs. 4.36/100 py in the discontinue arm; HR
0.48, 95%CI: 0.33, 0.70). Toxicity rates did not differ significantly between arms. Among
women randomized to continue ART, 189/827 (23%) had virologic failure; of the 155 with
resistance testing, 103 (66%) failed without resistance to their current regimen, suggesting
non-adherence.
Conclusions
Overall, serious clinical events were rare among young HIV-positive post-partum women
with high CD4 cell counts. Continued ART was safe and was associated with a halving of
the rate of WHO 2/3 conditions. Virologic failure rates were high, underscoring the urgent
need to improve adherence in this population.
Trial registration
ClinicalTrials.gov NCT00955968
Introduction
Over the past two decades, considerable progress has been made in the prevention of perinatal
HIV transmission[1,2]. Strategies for the prevention of perinatal transmission among asymp-
tomatic women with early stage HIV infection need to balance the impact of preventing trans-
mission and optimizing infant outcomes with preserving maternal health. Concerns about
high rates of maternal morbidity postpartum[3] and health risks of discontinuing antiretrovi-
ral therapy (ART) emanating from the Strategies for Management of Antiretroviral Therapy
(SMART) study, coupled with strong evidence demonstrating a reduction in the risk of HIV
transmission during the use of ART[4] and the clinical benefit from ART among non pregnant
women and men with higher CD4 + T-cell counts[5] has led to the evolution of strategies for
perinatal HIV transmission that favor the continuous use of triple drug ART for life (herein
referred to as ART), also known as Option B+[6]. Concerns about maternal toxicity, possible
risks for premature delivery during longer term fetal exposure to ART, challenges to maternal
adherence during the postpartum period leading to antiretroviral resistance, and the lack of
randomized clinical trial data evaluating the benefits of postpartum ART in women with
higher CD4+ T-cell counts have led others to advocate for the rigorous evaluation of the use of
short term ART interventions among pregnant women with higher CD4 + T-cells[7–10].
The “HAART Standard” (HS) component of the Promoting Maternal and Infant Safety
Everywhere (PROMISE) trial (NCT00955968) was designed to examine the risks and benefits
of continued ART compared to stopping ART after delivery and re-initiating treatment when
CD4 + T-cell counts fell below 350 cells/mm3 among non-breastfeeding women with CD4
+ T-cell counts 400 cells/mm3 in the setting of a randomized clinical trial. The trial was
planned for settings where ART was the standard of care for the prevention of perinatal HIV
transmssion in 2009.
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Materials and methods
The “HAART Standard” component of the PROMISE studies was conducted by the Interna-
tional Maternal, Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) in collabora-
tion with the AIDS Clinical Trials Network (ACTG). The trial was a randomized strategy trial
conducted among clinically stable HIV-infected pregnant women, antiretroviral-naïve except
for prior use in pregnancy, without other indications for ART, who received ART during preg-
nancy for the purpose of preventing perinatal HIV transmission. Women 18 years of age or
who had attained the minimum age of independent consent as defined by the local institu-
tional review board were eligible to enroll if they had documentation of a CD4 + T-cell count
of400 cells/mm3 within the 120 days prior to the start of ART during the current pregnancy
and evidence that CD4 + T-cell count remained 400 cells/mm3 during the 45 days prior to
entry while on ART. Participants could not have a clinical indication for ART, including any
WHO clinical stage 3 or 4 condition, or any clinically significant illness within 30 days prior to
entry. The study was approved by the institutional review board or ethics committee at each
participating site and written informed consent was obtained from all participants. During the
trial as new guidelines were released with higher CD4 + T-cell count threshholds for ART eligi-
bility, participants were informed and re-consented.
Study design
This open-label randomized clinical trial evaluated two strategies for the management of ART
among postpartum women within 42 days after delivery: continuing ART or discontinuing
ART and restarting when clinically indicated. The study was conducted at sites in Argentina,
Botswana, Brazil, China, Haiti, Peru, Thailand and the United States. In step 1 of the trial, par-
ticipants were randomized in a 1:1 ratio to either continue or discontinue ART by a web-
based, central randomization system on the IMPAACT Data Management Center’s portal
which used permuted block allocation (block size 4) with stratification by screening CD4+ cell
count (400–499 versus 500–749 versus 750 cells/mm3) and dynamic balancing by study site
[11]. A site staff member enrolled participants by answering eligibility and stratification ques-
tions in the randomization system, and if passed, the system randomized the participant and
generated a coded study identification number which the site pharmacist compared to a mas-
ter list and dispensed the corresponding study drug.
Participants randomized to discontinue ART in step 1 entered step 2 and restarted ART if
they met one of the following criteria; 1) developed an AIDS-defining/WHO Stage 4 illness, 2)
had a confirmed CD4+ T-cell count<350 cells/mm3, 3) developed a clinical condition (other
than pregnancy) considered an indication for ART by country-specific guidelines during the
period of January 2010- July 2015 or 4) otherwise required ART as determined in consultation
with the study clinical management committee. Women in step 1 or step 2 entered step 3 if
they developed a medical indication to change ART.
The preferred study-supplied ART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed
dose combination emtricitabine/tenofovir (FTC/TDF). This regimen was chosen because it
was the preferred regimen for use in pregnancy by the Department of Health and Human Ser-
vices (DHHS) guidelines at the time the study was designed[12]. Additional study-supplied
antiretrovirals (ARVs) included fixed dose combination lamivudine/zidovudine (3TC/ZDV),
lamivudine (3TC), zidovudine (ZDV), tenofovir disoproxil fumarate (TDF), fixed dose combi-
nation emtricitabine/tenofovir disoproxil fumarate/rilpivirine (FTC/TDF/RPV), atazanavir
(ATV), raltegravir (RAL), and ritonavir (RTV). Study clinicians in conjunction with partici-
pants were allowed to determine the optimal drug combination for each participant. Regimens
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not provided by the study were allowed if they included three or more agents from two or
more classes of ART.
Participants were seen for clinical and safety evaluations at four weeks and at 12 weeks, and
every 12 weeks thereafter. If a change in treatment was required for disease progression or due
to toxicity, participants were seen at four weeks after ART regimen change and then returned
to the every 12 week schedule. HIV viral load was used to maximize the benefits of ART and to
determine when treatment should be changed. HIV-1 RNA was evaluated in real time at base-
line and among those randomized to continue ART, at weeks four and 12 after entry andevery
12 weeks thereafter. A viral load was also obtained at every step change.
Study endpoints
The primary composite endpoint included death from any cause, AIDS-defining illness, and
serious non-AIDS-defining cardiovascular, serious renal, and hepatic events. The qualifying
illnesses and conditions corresponding to the primary endpoints are as follows: AIDS-defining
illness refers to the WHO Clinical Stage 4 conditions; cardiovascular endpoints include myo-
cardial infarction, stroke or coronary artery disease requiring revascularization; renal end-
points included end stage renal disease; and hepatic endpoints include decompensated liver
disease (cirrhosis). Secondary endpoints reported here include: 1) composite endpoint of
HIV/AIDS related events (defined as WHO Stage 4 conditions, pulmonary tuberculosis and
serious bacterial infections) or death, 2) composite endpoint of HIV/AIDS-related event or
WHO Clinical Stage 2 or 3 event, 3) safety, and 4) HIV-1 viral resistance to ART at the time of
virologic failure. The safety endpoint is a composite of a grade 3 or 4 sign or symptom, or
grade 2, 3, or 4 hematology or chemistry result, whichever came first. Post-hoc analysis
included comparing WHO Stage 2 and 3 events in those randomized to continue versus dis-
continue ART.
Statistical analysis
The planned sample size of 2000 was selected to provide 90% power to detect a 50% reduction
from an annualized primary event rate of 2.07% in the discontinue ART group. Analyses used
the principle of intention-to-treat and included all women randomized. Comparisons between
treatment groups were based on log rank tests and Cox regression models for estimation of
treatment effect sizes[13]. The distributions of time until the first event occurred were summa-
rized using Kaplan-Meier plots[14]. Point estimates, p-values, and 95% confidence intervals
were not adjusted for interim efficacy analyses due to the conservative O’Brien-Fleming error
spending function used[15]. The analyses presented here reflect follow-up until July 7, 2015,
when participants were informed about the Strategic Timing of AntiRetroviral Treatment
(START) trial results[16] and all participants were offered ART. A two-sided p-value less than
0.05 was considered statistically significant. Statistical analyses were performed using Statistical
Analysis System (SAS) software version 9.4 (SAS Institute).
Interim monitoring
The study was reviewed by an independent National Institute of Allergy and Infectious Dis-
eases (NIAID)-sponsored Data Safety and Monitoring Board (DSMB). The DSMB reviewed
annual interim analyses of safety, study logistics, and an assessment of the accuracy of the
assumed annualized primary endpoint rate, and two interim analyses of efficacy and futility.
Due to slow accrual, the DSMB approved curtailing enrollment at a minimum of 1630 partici-
pants in November 2014. The reduced sample size retained 88% power to detect the original
effect size due to the additional follow-up time contributed by those enrolled early in the trial.
Randomized trial of post-partum ART in HIV
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In November 2015, the DSMB recommended that the primary analysis should include only
follow-up until July 7, 2015, when all participants were offered ART, and that the study team
should be unblinded so that they could begin the primary analysis and publish the results.
Results and discussion
Study patients
From January 2010 through November 2014, 1653 women at 52 were randomly assigned to
continue or discontinue ART within 42 days after delivery. One woman withdrew consent and
discontinued study follow-up on the day she was randomized and was not included in the
final analysis. The two study groups were well balanced at entry (Table 1). The median age was
28 years and major racial categories were Black African (28%), Asian (25%), and White (15%).
Median entry CD4+ T-count was 696 cells/mm3, median ART exposure prior to delivery was
19 weeks (IQR 13–24) and 94% had an entry HIV-1 RNA < 1000 copies/ml. The median fol-
low-up time was 2.3 years (range: 10, 279 weeks) and duration of follow-up did not differ sig-
nificantly across the randomization arms.
Of the 1652 women included in the analysis, 149 women (9%) discontinued follow-up pre-
maturely. An additional 107 women (7%) were taken off study due to site closure. A total of 136
women in the continue arm and 126 in the discontinue arm were off study. Study participant
disposition is shown in Fig 1. Reasons participants went off study are summarized in S1 Fig.
Use of antiretroviral therapy
Of the women enrolled, 1,266 (77%) were receiving a protease inhibitor (PI) containing ART
regimen just prior to randomization. Ninety percent of the study participants randomized to
continue ART were treated with a ritonavir boosted protease inhibitor regimen: LPV/RTV in
76%, atazanavir/ritonavir in 13% and other PIs in the remaining 1%. Non-nucleoside reverse
transcriptase inhibitor (NNRTI) based ART was used by 8% of participants with efavirenz
accounting for 7% overall. Integrase inhibitor-based ART was used by <1% of study partici-
pants. Boosted PI were predominantly used across all countries with the exception of Haiti,
where approximately half of the participants used efavirenz-based ART. Post randomization
ART usage among those randomized to continue ART is summarized in Table 2.
Adherence to randomization strategy
As of July 7, 2015 ART had been started in 102 (12%) of the discontinue group prior to reach-
ing a CD4 count of 350 cells/mm3 (5% per year). In contrast 119 (15%) of those randomized to
continue ART prematurely discontinued ART (6.5% per year).
Study endpoints
After a median follow-up of 2.3 years, ten participants experienced a primary composite end-
point event with an overall rate of 0.26%, significantly lower than expected and not signifi-
cantly different between arms: 0.21 per 100 person years (py) in the continue arm, compared
to 0.31 per 100 py in the discontinue arm, HR 0.68 (95% CI: 0.19, 2.40; p 0.54). The events are
described in Table 3.
Participants randomized to continue ART experienced a significantly lower rate of the pre-
specified secondary endpoint that included a range of clinical outcomes (HIV/AIDS related
event or WHO stage 2–3 event). For this endpoint, 57 women (3.09 events per 100 py) in the
continue arm, compared to 97 (5.37 events per 100 py) in the discontinue arm experienced an
event, with a hazard ratio of 0.58 (95% CI: 0.42, 0.80; p< 0.001). This difference was primarily
Randomized trial of post-partum ART in HIV
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Table 1. Baseline Characteristics.
Characteristic Continue ART
(N = 827)
Discontinue ART
(N = 825)
Total
(N = 1652)
Country Argentina
Botswana
Brazil
China
Haiti
Peru
Thailand
USA
20(2%)
230 (28%)
259 (31%)
52 (6%)
32 (4%)
6 (1%)
156 (19%)
72 (9%)
25 (3%)
227 (28%)
255 (31%)
52 (6%)
29 (4%)
9 (1%)
151 (18%)
77 (9%)
45(3%)
Racea Asian 209 (25%) 203 (25%) 412 (25%)
Black or African American 58 (7%) 58 (7%) 116 (7%)
White 123 (15%) 127 (15%) 250 (15%)
American Indian 1 (0%) 1 (0%) 2 (0%)
Alaska Native 0 (0%) 1 (0%) 1 (0%)
Black African 230 (28%) 227 (28%) 457 (28%)
Black of African origin 77 (9%) 70 (8%) 147 (9%)
Mestizo 6 (1%) 8 (1%) 14 (1%)
Mixed Black 73 (9%) 76 (9%) 149 (9%)
Mixed Native 0 (0%) 4 (0%) 4 (0%)
Native (native Brazilian-Xavante/Kaigang/Guarani
etc)
1 (0%) 1 (0%) 2 (0%)
Other 31 (4%) 31 (4%) 62 (4%)
Subject does not know 4 (0%) 2 (0%) 6 (0%)
Race not available to clinic 14 (2%) 16 (2%) 30 (2%)
BMI at Entry (kg/m2) N 812 801 1613
Median (Q1-Q3) 24.4 (21.7–
28.0)
24.6 (21.8–28.3) 24.5 (21.8–
28.1)
# missing 15 24 39
WHO Stage at Entry Clinical Stage I 810 (98%) 811 (99%) 1,621 (98%)
Clinical Stage II 16 (2%) 11 (1%) 27 (2%)
Clinical Stage III 1 (0%) 1 (0%) 2 (0%)
# missing 0 2 2
Duration of ART prior to study entry, weeks N 827 825 1652
Median (Q1-Q3) 17 (11–23) 17 (11–23) 17 (11–23)
# missing 0 0 0
ART regimen prior to Entry HAART including
Boosted PI
620 (75%) 612 (74%) 1,232 (75%)
HAART including
Non-boosted PI
12 (1%) 16 (2%) 28 (2%)
HAART including NNRTI [EFV] 180 (22%) 172 (21%) 352 (21%)
HAART including NNRTI [NVP] 4 (0%) 8 (1%) 12 (1%)
HAART including NNRTI [RPV] 1 (0%) 1 (0%) 2 (0%)
HAART including NNRTI and PI 1 (0%) 0 (0%) 1 (0%)
Three or more NRTIs 3 (0%) 11(1%) 14 (1%)
Hepatitis B surface antigen positive Positive 29 (4%) 28 (3%) 57 (3%)
Negative 771 (93%) 768 (93%) 1,539 (93%)
Indeterminate 1 (0%) 0 (0%) 1 (0%)
Not obtained, Hep B antibody +ve 20 (2%) 23 (3%) 43 (3%)
Not obtained 6 (1%) 6 (1%) 12 (1%)
(Continued)
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due to differences in rates of WHO Stage 2 and 3 events: 2.08 events per 100 py in the continue
arm vs 4.36 events per 100 py in the discontinue arm, with a HR of 0.48 (95% CI: 0.33, 0.70;
p< 0.001). The distributions of the time until the first event occurred are shown in Fig 2 for
the primary and secondary efficacy and safety endpoints.
Trajectories of CD4 + T-cell counts over time are shown in Fig 3. The percentage of partici-
pants in the discontinue arm with CD4+ T-cell counts below 350 cells/mm3 was less than
<10% throughout follow-up, with the exception of week 192 when it rose transiently to 15%.
In contrast, among those randomized to continue ART, the percentage of participants whose
CD4+ T-cell count had dropped below 350 cells was less than 4% throughout follow-up.
The primary safety endpoint of selected grade 2 and grades 3 and 4 hematologic and
chemistry abnormalities occurred in 260 of the continue arm participants (18.4 per 100 py)
and in 234 of the discontinue arm (15.6 per 100 py) yielding a HR of 1.16 (95% CI: 0.97, 1.38
p = 0.10). A complete listing of the specific laboratory adverse events by treatment arm is
included in Table 4. Notably, grade 2–4 renal events occurred in less than one percent of the
study population. Thrombocytopenia was more common in the discontinue group (18 events)
compared to the continue group (four events). When grade 3 and 4 adverse event rates were
compared between treatment arms, the rates were numerically but non-significantly higher in
the continue group compared to the discontinue group (12.0 per 100 py. vs. 9.8 per 100py
respectively, HR 1.20, 95% CI: 0.98, 1.49; p = 0.08), with transaminase elevations and choles-
terol elevations accounting for the higher rate in the continue group.
Virologic failure and HIV-1 drug resistance
Virologic failure among the women randomized to continue ART was defined as two succes-
sive measurements of HIV-1 RNA above 1000 copies/ml at or after 24 weeks of ART. A total
Table 1. (Continued)
Characteristic Continue ART
(N = 827)
Discontinue ART
(N = 825)
Total
(N = 1652)
Hepatitis B surface antibody positive Positive 263 (32%) 248 (30%) 511 (31%)
Negative 424 (51%) 425 (52%) 849 (51%)
Indeterminate 1 (0%) 2 (0%) 3 (0%)
Not obtained, Hep B antigen +ve or -ve 138 (17%) 148 (18%) 286 (17%)
Not obtained 1 (0%) 2 (0%) 3 (0%)
Screening CD4+ cell count on ART (cells/
mm3)
N 827 825 1652
Median (Q1-Q3) 696 (575–870) 695 (575–868) 696 (575–869)
# missing 0 0 0
Pre-ART CD4+ cell count (cells/mm3) N 827 825 1652
Median (Q1-Q3) 550 (461–682) 548 (463–677) 549 (462–680)
# missing 0 0 0
Plasma Viral Load at Entry (copies/ml) <400 744 (91%) 742 (91%) 1,486 (91%)
400–1000 30 (4%) 24 (3%) 54 (3%)
1000- <10000 32 (4%) 29 (4%) 61 (4%)
10000 - <100000 15 (2%) 24 (3%) 39 (2%)
> = 200000 1 (0%) 0 (0%) 1 (0%)
# missing 5 6 11
a For Race: Other—The 62 were coded as having a Race/Ethnicity of Hispanic (regardless of race).
https://doi.org/10.1371/journal.pone.0176009.t001
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of 293 women had at least one HIV-1 RNA above 1000 copies/ml, of these 92 re-suppressed on
the next measurement and 12 were lost to follow-up, hence 189 (23%) met the definition of
virologic failure. Of the 189 with confirmed virologic failure, 156 women had antiretroviral
drug resistance testing performed with available results. Fifty-two (33%) women had the pres-
ence of at least one mutation (includes polymorphisms) and 36 had evidence of HIV drug
resistance defined using the Stanford database (version 6.2). Among the 36 women with drug
resistance, 17 had evidence of resistance mutations not selected by the current ART regimen
and 19 had evidence of resistance selected by the current ART regimen. If all women who had
virologic failure and available resistance data are considered, this translates to 19/156 (12%)
overall who failed with resistance to their current ART. Virologic failure with resistance to the
current regimen was more common in women failing NNRTI containing regimens (7/9, 78%)
than those failing PI containing regimens (11/142, 8%). A summary of ART at the time of viro-
logic failure and resistance is included in Table 5.
Discussion
This is the first large multicenter randomized clinical trial to compare the strategy of stopping
or continuing ART in postpartum women with early stage HIV infection. The study demon-
strates a low rate of serious clinical events over 2.3 years of postpartum follow-up in both
Fig 1. CONSORT Flow Diagram.
https://doi.org/10.1371/journal.pone.0176009.g001
Randomized trial of post-partum ART in HIV
PLOS ONE | https://doi.org/10.1371/journal.pone.0176009 May 10, 2017 8 / 15
Table 2. ART use within 72 hours after randomization for the continue ART arm.
Continue ART
(N = 825)
Antiretroviral Regimen
Boosted Protease Inhibitor Regimens 744 (90%)
Lopinavir/r 625
Atazanvir/r 104
Darunavir/r 10
Fosamprenavir/r 3
Indinavir/r 2
Non-Boosted Protease Inhibitor Regimens 8 (<1%)
Atazanvir 6
Nelfinavir 2
Non-Nucleoside Reverse Transcriptase Inhibitor Regimens 65 (8%)
Efavirenz 56
Rilpivirine 8
Nevirapine 1
Nucleoside Reverse Transcriptase Regimens 2 (<1%)
ZDV+3TC+ABC 2
Intergrase Inhibitor Based Regimens 4 (<1%)
Raltegravir 2
Elvitegravir/Cobicistat 2
No Follow-up after the Entry Visit 2
https://doi.org/10.1371/journal.pone.0176009.t002
Table 3. Clinical Endpoints.
Endpoint (time to first event) Continue ART no. no./
100 py
Discontinue ART
no. no./ 100 py
Hazard Ratioc p-value
Primary Composite Endpoint (first of AIDS,Death,or
Serious Non-AIDS Cardio/Renal/Hepatic
4 0.21 6 0.31 0.68 (0.19, 2.40) 0.54
AIDS Defining (WHO 4) 2 0.10 3 0.15 0.67 (0.11, 4.01) 0.66
Death (including after AIDS event) 2 0.10 4 0.20 0.52 (0.09, 2.81) 0.44
Secondary Endpoints
Composite Endpoint of HIV/AIDS related eventsa and
WHO stage 2–3 events
57 3.09 97 5.37 0.58 (0.42, 0.80) <0.001
HIV/AIDS related events
Single Bacterial Pneumonia 10 0.52 14 0.73 0.72 (0.32, 1.62) 0.42
Grade 4 Bacterial infections 5 0.26 2 0.10 2.52 (0.49,12.98) 0.25
Bacterial infections resulting in hospitalization 14 0.73 14 0.73 1.00 (0.48, 2.11) 0.99
Bacterial infections causing death 0 NA 0 NA NA NA
Composite Endpoint of HIV/AIDS related event or death 27 1.42 30 1.57 0.91 (0.54, 1.52) 0.71
WHO 2–3 events (including WHO 2–3 diagnoses after
oserved WHO IV events)
39 2.08 80 4.36 0.48 (0.33, 0.70) <0.001
Toxicity Eventsb
Grade 2 Toxicity and above 260 18.4 234 15.6 0.86 (0.72, 1.03) 0.10
Grade 3 and 4 Toxicity 188 12.0 161 9.8 1.13 (0.86, 1.49) 0.08
aHIV/AIDS related events refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections.
bToxicity Event is defined as composite of the time to the first grade 3 or 4 sign or symptom, or grade 2, 3, or 4 hematology or chemistry event, whichever
comes first.
c The Hazard Ratio is for the Continue ART arm as compared to the Discontinue ART arm.
https://doi.org/10.1371/journal.pone.0176009.t003
Randomized trial of post-partum ART in HIV
PLOS ONE | https://doi.org/10.1371/journal.pone.0176009 May 10, 2017 9 / 15
arms. However, continuing ART was associated with a clinical benefit evidenced by a 50%
decrease in the rates of WHO 2 and 3 events compared with discontinuing ART. ART was safe
with low rates of toxicity in this young population where the majority were receiving a boosted
protease inhibitor combined with emtricitabine and tenofovir. These findings demonstrate a
very low rate of serious non-AIDS events among young women as compared to rates previ-
ously reported among studies that included populations who were older[5,16,17]. There are
several factors that may have contributed to these differences: 1) our study participants were
younger than those in other studies; 2) their baseline CD4+ T-cell count was higher; 3) our
study population exclusively consisted of women, whereas previous studies enrolled mostly
Fig 2. Survival Curves for the Primary and Secondary Endpoints. A) Composite endpoint of the first AIDS-defining illness, serious non-AIDS
defining cardiovascular, renal or hepatic event or death. B) Composite endpoint of the first WHO 2 or 3 event. C) Composite of first grade 3 or 4 sign
or symptom, or grade 2,3, or 4 hematology or chemistry event. D) Composite of the first grade 3 or 4 sign or symptom, or hematology or chemistry
event.
https://doi.org/10.1371/journal.pone.0176009.g002
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men. Importantly, the smaller size of our study and relatively short follow-up reduces our
power to detect differences between arms for the primary efficacy endpoint.
These findings help to inform current guidelines for the use of Test and Start and Option
B+ globally by highlighting an important challenge associated with this strategy. The relatively
high rates of virologic failure among women in the continue ART group underscore the
critical need to remove barriers to long-term adherence during the postpartum period. The
absence of HIV drug resistance among most participants with virologic failure on ART needs
to be interpreted cautiously given that the majority of participants were receiving a boosted PI
regimen, where resistance at the time of failure is often not associated with measurable drug
resistance and participants can often re-suppress HIV-1 RNA with continuation of the same
regimen[18]. However, It is important to highlight that standard genotypic testing, performed
by conventional sequencing, does not readily detect variants below 20% of the circulating
HIV-1 RNA population. In patients with poor adherence to a boosted PI regimen, deep
sequencing may detect minority PI-resistant variants, which likely represent early events in
resistance selection[19].
Our data portend higher rates of virologic failure with resistance in settings where efavir-
enz-based ART regimens are predominant. These findings underscore the importance of eval-
uating newer and potentially more durable antiretroviral agents such as integrase inhibitors
with a higher genetic barrier to drug resistance in pregnant and post-partum women.
The low rate of clinical progression observed in those randomized to discontinue ART
postpartum also provides some reassurance for women who cannot become virologically
Fig 3. CD4 Cell Counts Over time (Median, 10th and 90th percentile, and the proportion <350 cells/mm). The median CD4 cell
counts in the continue (green) and discontinue (red) arms are show at each follow-up visit. The proportion with a CD4 count below 350
cells/mm3 are shown across the top of the figure at each timepoint.
https://doi.org/10.1371/journal.pone.0176009.g003
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suppressed on currently available ART, due to toxicity or tolerability or, who require observa-
tion off ART due to complex multifactorial issues that preclude adherence. Previous observa-
tional follow-up studies of postpartum women in African settings identified a low rate of
progression to WHO Stage 4 or death among women with CD4+ T-cell counts > 550 cells/
mm3 and our data extend this finding[20]. These findings may also have implications for the
design of cure research studies that include an interruption of treatment to evaluate the impact
of an intervention to purge the reservoir by providing insight into the safety of discontinuing
ART among younger patients without a history of immunodeficiency. It is important to note
that the duration of ART in these participants prior to discontinuation was only 19 weeks on
average, however.
The strengths of our study include the randomized design, the conduct in multiple coun-
tries including both lower and middle income settings, and rigorous assessments of safety, effi-
cacy and virologic outcomes. Weaknesses include the smaller than planned sample size, lower
than expected event rate resulting in reduced power, and the relatively short follow-up. The
Table 4. Laboratory Adverse Eventsa.
Toxicities
Continue ART (n = 827)
Grade
Discontinue ART (n = 825)
Grade
2 3 4 Total 2 3 4 Total
Any Chemistry
Event
24 (3%) 81 (10%) 22 (3%) 127 (15%) 18 (2%) 65 (8%) 15 (2%) 98(12%)
Any Hepatic 26 (3%) 13 (2%) 7 (< 1%) 46 (6%) 20 (2%) 12 (2%) 4 (< 1%) 36 (4%)
ALT 16 10 7 33 21 12 2 35
AST 12 10 5 27 10 5 3 18
Indirect Bilirubin 5 2 0 7 0 0 0 0
Renal (Creatinine) 5 (<1%) 0(0%) 0 (0%) 5 (<1%) 1 (< 1%) 0 (0%) 1 (<1%) 2 (< 1%)
Any General Chemistry 0 (0%) 25 (3%) 13 (2%) 38 (5%) 0 (0%) 24 (3%) 8 (1%) 32 (4%)
Phosphorus 0 19 2 21 0 14 0 14
Sodium 0 5 7 12 0 8 5 13
Potassium 0 4 2 6 0 2 2 4
Alkaline Phosphatase 0 0 2 2 0 0 0 0
Bicarbonate 0 0 0 0 0 0 1 1
Any Metabolic 0 (0%) 44 (5%) 2 (< 1%) 46 (6%) 0 (0%) 30 (4%) 2 (< 1%) 32 (4%)
LDL (fasting) 0 36 0 36 0 25 0 25
LDL (non-fasting) 0 1 0 1 0 0 0 0
Total cholesterol (fasting) 0 21 0 21 0 14 0 14
Total cholesterol (non-fasting) 0 1 0 1 0 0 0 0
Glucose (non-fasting) 0 3 0 3 0 3 1 4
Triglycerides (fasting) 0 4 2 6 0 0 1 1
HDL (fasting) 0 0 0 0 0 1 0 1
Any Endocrine Metabolic 0 (0%) 4 (<1%) 0 (0%) 4 (<1%) 0 (0%) 5(<1%) 0(0%) 5(<1%)
Glucose (fasting) 0 4 0 4 0 5 0 5
Any Hematologic Event 68 (8%) 25 (3%) 10 (1%) 98 (12%) 71 (9%) 26 (3%) 14 (2%) 111 (14%)
Platelets 3 0 1 4 14 1 3 18
Hemoglobin 21 7 8 36 15 8 9 32
White Blood Cells 1 0 0 1 4 1 0 5
Absolute Neutrophil Count 43 18 1 62 44 16 2 62
aEach participant is counted once at the highest grade for the specific safety event, once for the safety category total, and once for the overall total.
https://doi.org/10.1371/journal.pone.0176009.t004
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study also did not follow the infants and cannot provide any information about infant out-
comes. Additionally, the use of a boosted PI regimen in our trial, which was based on US
Guidelines at the time the trial was designed, may reduce the generalizability of our findings to
settings where efavirenz has become the preferred agent for treatment. The efficacy of ART
with efavirenz as compared to a boosted PI might be expected to be similar, as was previously
demonstrated among pregnant women in Uganda[21], however the consequences of non-
adherence with respect to the development of HIV-1 drug resistance when failure occurs may
result in more clinically significant drug resistance with efavirenz.
Conclusion
In conclusion, continuation of ART in the post-partum period is of clinical benefit to women
with early HIV infection and preserved CD4 cell counts. Our study highlights the need to
improve adherence to long term ART in this vulnerable population. These efforts will be criti-
cal in order to reach the collective goal of improving the health of all people with HIV infection
and for reducing the rates of new infections.
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